Ahmedabad: Zydus Lifesciences Limited has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Pimavanserin Capsules, 34 mg (USRLD: Nuplazid Capsules) and Pimavanserin Tablets, 10 mg (USRLD: Nuplazid Tablets), respectively.
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
Both the tablets and the capsules will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Pimavanserin Capsules, 34 mg had annual sales of USD 149 mn and Pimavanserin Tablets, 10 mg had annual sales of USD 10 mn in the United States (IQVIA Dec. Nov. 2023). The group now has 384 approvals and has so far filed over 448* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Shweta Rai takes over as MD of Bayer Zydus Pharma
Formerly known as Cadila Healthcare Limited, Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the production of generic drugs. Cadila was founded in 1952 by Ramanbhai Patel.
Read also: Zydus Lifesciences gets USFDA nod to begin Phase II clinical trial of ZYIL1 in Parkinson's disease patients
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!